Agree, but we need a loi or mou from a pharma to get it moving. The market does not have any idea (quite rightly) where they are on the commercialisation path and at what point pharma will enter. This could well occur at any time, but the market is failing to recognise the accretive value these results are making to the value of the science and the compound.
